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Abstract
Background: Topical glucocorticosteroids are the first line therapy for airway inflammation. Modern compounds with
higher efficacy have been developed, but head-to-head comparison studies are sparse.
Objective: To compare the activity of two intranasal glucocorticoids, fluticasone furoate (FF) and mometasone furoate (MF)
with respect to the inhibition of T helper (Th)1, Th2 and Th17 cytokine release in airway mucosa.
Methods: We used an ex-vivo human nasal mucosal tissue model and employed pre- and post- Staphylococcus aureus
enterotoxin B (SEB)-challenge incubations with various time intervals and drug concentrations to mimic typical clinical
situations of preventive or therapeutic use.
Results: At a fixed concentration of 10210 M, FF had significantly higher suppressive effects on interferon (IFN)-c, interleukin
(IL)-2 and IL-17 release, but not IL-5 or tumor necrosis factor (TNF)-a, vs. MF. While the maximal suppressive activity was
maintained when FF was added before or after tissue stimulation, the cytokine suppression capacity of MF appeared to be
compromised when SEB-induced cell activation preceded the addition of the drug. In a pre-challenge incubation setting
with removal of excess drug concentrations, MF approached inhibition of IL-5 and TNF-a after 6 and 24 hours while FF
maximally blocked the release of these cytokines right after pre-incubation. Furthermore, FF suppressed a wider range of T
helper cytokines compared to MF.
Conclusion: The study demonstrates the potential of our human mucosal model and shows marked differences in the
ability to suppress the release of various cytokines in pre- and post-challenge settings between FF and MF mimicking typical
clinical situations of preventive or therapeutic use.
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Introduction
Topical glucocorticosteroids (GCS) are the first line therapy for
allergic rhinitis, sinusitis and nasal polyposis [1,2]. Over the last
decades, GCS compounds with higher efficacy and less systemic
bioavailability have been developed, with fluticasone furoate (FF)
as the latest compound being introduced to the market [3,4]. FF
has the molecular backbone of fluticasone that is also present in
fluticasone propionate (FP) but the properties of both molecules
are distinctly different [5]. Although FF has a higher receptor
affinity and better tissue retention compared to mometasone
furoate (MF) [6,7], the clinical advantage of FF over MF has not
been demonstrated yet in rigorous clinical trials. In absence of
head-to-head comparison studies for both drugs, such comparison
may also be extrapolated from ex-vivo human nasal mucosal
models using diseased and control mucosa with different stimuli.
To optimally respond to the expectations of the patients, a nasal
topical corticosteroid should have a fast onset of action, which
requires a fast uptake and strong binding to the glucocorticoid
receptor, translocation of the glucocorticoid receptor complex into
the nucleus and interaction with glucocorticoid response elements
(GREs), resulting in a long duration of action allowing for once
daily application, and a high efficacy in suppressing the local
inflammation with a broad panel of cytokines from Th1, Th2 and
Th17 cells included [8].
We have developed an ex-vivo human mucosal tissue model for
Staphylococcus aureus enterotoxin (SEB) induced T-effector cell
activation [9,10], in which we can interfere with glucocorticoster-
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e93754
oids and other therapeutic compounds. The model is very robust
and reproducible, but sensitive to demonstrate differences in the
efficacy of compounds. At the same time, it is very close to the
real-life situation and may thus predict the clinical outcome. We
here used this model for a comparative study of FF vs MF in their
efficacy, duration of their effect and onset of action. The inhibition
of the release of a pattern of Th1, Th2 and Th17 cytokines was
studied in three groups of experiments.
The experiments were designed to reflect optimal conditions for
the drugs with incubation prior to and together with the stimulus,
or real life conditions, with application of the drugs after initiation
of disease exacerbation by a stimulus, and finally to study onset
and duration of action after a defined exposure to the drug.
Methods
Human specimen
Nasal polyp samples were collected during functional endo-
scopic sinus surgery from 9 patients (median age, 52 years; range,
28-72 years; 5 men and 4 women). Nasal polyposis was diagnosed
on the basis of symptoms, clinical examination, nasal endoscopy,
and sinus computed tomography scan according to the European
Position Paper on Rhinosinusitis and Nasal Polyps guidelines [1].
The atopic status of patients was evaluated by skin prick tests
(SPTs) with the European standard panel of 14 inhalant allergens.
Negative and positive controls (10 mg/mL histamine solution)
were included with each SPT. 5 nasal polyp patients with positive
SPT for at least 1 of the most common aeroallergens, 4 negative.
Three patients reported mild asthma in their history, and one
patient reported aspirin intolerance.
All patients were asked to refrain from topical or oral
corticosteroids or antibiotics 4 weeks preoperatively and gave
their written informed consent and the ethics committee of the
Ghent University Hospital approved the study.
Mechanical disruption of human nasal tissue
The nasal tissue was cut thoroughly as described before [9,10]
in tissue culture medium (TCM) of RPMI 1640 (Sigma-Aldrich,
Bornem, Belgium) containing 2 mmol/L L-glutamine (Invitrogen,
Merelbeke, Belgium), antibiotics (50 IU/mL penicillin and
50 mg/mL streptomycin; Invitrogen), and 0.1% BSA (Sigma).
The tissue was passed through a mesh (+0.9 mm2) to achieve
comparable fragments. The fragments (+0.9 mm3) were weighed,
suspended as 0.04 g tissue/mL TCM and incubated for 1 hour at
37uC, 5% CO2. In a following step tissue fragments were washed,
resuspended in the appropriate amount of TCM, and distributed
into a 48-well plate (BD Falcon, VWR International, Belgium)
with 0.5 mL tissue fragment suspension in each well.
Pre-challenge incubation - the experiment to compare
the effect of compounds under optimal conditions
The polyp tissue fragments were pre-incubated with TCM
(RPMI+DMSO), 1028 M, 1029 M, 10210 M and 10211 M
fluticasone furoate (FF; GSK Stevenage, UK) (29,6 mg FF
dissolved in 5500 ml DMSO made a stock solution of 10 mM
(1022 M)) or mometasone furoate (MF; Schering Plough)
(52,14 mg in 10 ml DMSO made a stock solution of 10 mM
(1022 M)) for 1 hour at 37uC/5% CO2 and then stimulated with
TCM (negative control) or 0.5 mg/mL SEB (# S4881; Sigma) for
24 hours. The final concentration of DMSO was 0.1% in each
well. Aliquots of the supernatants were stored immediately at
220uC until analysis of cytokines.T
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Post challenge incubation - the experiment to compare
the effect of drugs on a running stimulation
The polyp tissue fragments were stimulated with TCM (negative
control) or 0.5 mg/mL SEB 1 hour or 2 hours or 4 hours then
followed with TCM, 1028 M, 1029 M, 10210 M and 10211 M FF
or MF for 24 hour at 37uC/5% CO2. Aliquots of the supernatants
were stored immediately at 220uC until analysis of cytokines.
Pre-challenge incubation with time interval - the
experiment to compare the uptake and translocation of
compounds
The polyp tissue fragments were pre-incubated with TCM,
1028 M, 1029 M, 10210 M and 10211 M FF or MF for 1 hour at
37uC/5% CO2, washed 2 times with TCM, and after 0 hour,
6 hours and 24 hours stimulated with TCM (negative control) or
0.5 mg/mL SEB for 24 hours. Aliquots of the supernatants were
stored immediately at 220uC until analysis of cytokines.
Measurements of T effector cell cytokines in
supernatants of stimulated tissue fragments
Concentrations of the cytokines IFN-c, IL-5 and IL-17, IL-1b,
TNF-a, IL-2, IL-4, IL-8, IL-6, IL-10, IL-12p70, and IL-13 were
measured in tissue supernatants obtained after the ex vivo
stimulations using Multi-spot assays (Meso Scale Discovery,
Gaithersburg, Maryland, USA) following the instructions of the
manufacture. The plates were analyzed by using a Sector Imager
6000 (Meso Scale Discovery). Calculations of maximum percent-
age of inhibition for the different compounds, time points and
cytokines were done.
Statistical analysis
Statistical analysis was performed by using the Wilcoxon test
(for paired comparisons). The Mann-Whitney U test was used for
between-group (unpaired) comparisons. P values of less than .05
were considered statistically significant.
Results
Under optimal conditions, the suppressive effect of FF is
superior to MF
FF and MF showed a dose-dependent suppressive effect on the
release of IFN-c, IL-2, IL-5, IL-17, and TNF-a upon stimulation.
There were no significant differences in maximum percentage of
inhibition of major cytokines between FF and MF after pre-
challenge incubation conditions (Table 1). However, FF reached a
significant suppressive effect at a 1-molar or lower concentration
for all cytokines. We further calculated the percentage of inhibition
at a fixed concentration of 10-10 M; FF had a significantly higher
suppressive effect on IFN-c, IL-2 and IL-17 release vs. MF
(Figure 1).
Upon challenge with SEB, FF has a stronger effect at
lower concentrations compared to MF
SEB stimulation resulted in a strong inflammation with the
release of all cytokines, which was reduced with both drugs. Added
an hour after SEB, FF showed a higher max. % inhibition on the
release of IFN-c, IL-2, IL-5, IL17, and TNF-a over 24 hours
compared to MF (Table 2 and Figure 2). The maximum %
inhibition was similar when drugs were added after 1, 2 or 4 h
after SEB stimulation (data not provided).
Onset of action is significantly faster with FF vs. MF, and
the suppressive effects of FF are superior to MF for IFN-c,
IL-2 and IL-17
Polyp tissue fragments were incubated with FF or MF for
1 hour, then washed to remove drug not bound to the tissue, and
stimulated with SEB immediately or after 6 or 24 hours. Both
drugs showed a time dependent dynamic suppression of IFN-c, IL-
2, IL-17 and TNF-a release. FF showed a much faster uptake and
suppressive effect after 1-hour incubation compare to MF, the max
% inhibition was significantly superior for FF vs. MF (P,0.05).
Figure 1. Nasal polyp tissue (n=9) was pre-incubated with FF or MF at different concentrations for 1 hour and consequently
stimulated with SEB for 24 hours (pre-challenge incubation). % inhibition of cytokine release was calculated at a fixed concentration of
10210 M; FF had a significantly higher suppressive effect on IFN-c, IL-2 and IL-17 release vs. MF.
doi:10.1371/journal.pone.0093754.g001
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Especially for IL-5, 1-hour incubation of the tissue with FF
resulted in an immediate maximum % inhibition, whereas an
inhibitory effect in the same range needed at least 6 hours with
MF (Table 3 and Figure 3). For other cytokines, the inhibitory
activity of FF always remained superior to MF even when
stimulated after 6 or 24 hours.
Stimulation with SEB after 24 hours revealed a true 24 hours
effect of FF on cytokine release in the range of 74 to 94% for all
cytokines, after just one hour of incubation with the compound.
Discussion
In the current investigation we compared the effects of
fluticasone furoate (FF) and mometasone furoate (MF) on the
release of a pattern of Th1, Th2 and Th17 cytokines from human
nasal polyp tissue. We simulated three possible real-life drug-use
patterns including pre- and post-challenge exposure with FF or
MF. In all experimental settings we observed stronger effects of FF
compared to MF in terms of concentrations necessary to suppress
cytokine release, onset of action, maximal inhibition of release and
range of cytokines that could be suppressed.
A typical clinical situation would be the initiation of drug
therapy after allergen exposure or onset of symptoms. This setting
was mimicked by a post-challenge incubation with a concentration
range of 1028 to 10211 M FF and MF. We observed a
concentration-dependent inhibition of cytokine release, which
was stronger for FF compared to MF. The maximal inhibition
achieved by FF was statistically significantly higher than for MF,
which did not suppress IFN-c and TNF-a. The experimental
setting can be reversed to a pre-challenge exposure resembling a
prophylactic use of drugs. In this setup the corticosteroids were
pre-incubated with the nasal polyp tissue fragments for one hour
before SEB was supplemented. Under these conditions, the
maximal cytokine inhibition was not significantly different
between FF and MF, but FF consistently inhibited cytokine
release at lower concentrations compared to MF. At concentra-
tions as low as 10-10 M, FF showed a significantly higher
suppressive effect versus IL-2, IL-17 and IFN-c secretion
compared to MF. Interestingly, when the extent of inhibitory
effects in this pre- versus the post-challenge exposure setting are
compared, it is striking that FF produced maximal inhibition of IL-
2, IL-5, IL-17, IFN-c and TNF-a in comparable magnitudes in
both experimental setups. In contrast, the maximal inhibition of
cytokine release by MF was compromised in the post-challenge
incubation setting.
The third experimental setting we designed to mimic a
preventive use of intranasal glucocorticoids. In a clinical context,
any excess drug that is not taken up into the nasal tissue cells will
be rapidly removed by mucociliary clearance within about 30 min
[11]. This was mimicked by washing the tissue in our setup.
Subsequently, exposure with SEB was either performed immedi-
ately after washing off excess glucocorticoids (t = 0), or after
another 6 or 24 hours, respectively. Generally, FF inhibited the
cytokine release significantly stronger and at earlier time points
than MF. Especially the release of IL-5 and TNF-a was most
effectively suppressed even by low concentrations of FF and
irrespectively of the time interval between removal of the drug
excess and exposure with SEB. Thus, the inhibitory activity of FF
fully unfolded after only one hour incubation with the drug and
was not attenuated over the evaluated time interval. The
observation that FF still yielded a very potent suppression in
cytokine production by SEB after 24 hours, while the tissue
fragments were only exposed to the drug for one hour, is consistent
with our previous results that showed a fast uptake and a high
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binding of FF to human nasal tissue [7] and with the report that
FF was still detectable in cell nuclei 30 hours after treatment with
this drug [12,13]. Moreover, FF revealed a longer duration of
action, characterized by inhibition of GM-CSF release compared
to fluticasone propionate and budesonide.
However, in this pre-challenge incubation with subsequent drug
removal not all cytokines were influenced to the same extent by
the two corticosteroids. Specifically, the maximal inhibition of
release of IL-5 and TNF-a was similar for FF and MF when the
human nasal polyp tissue was challenged with SEB 6 and 24 hours
after incubation with the glucocorticoids. In contrast, this was not
observed for IL-2, IL-17 and IFN-c, the release of which was
significantly more inhibited by FF compared to MF over all
analyzed time intervals. Furthermore, the release of IL-5 and
TNF-a was already almost completely blocked by lowest
concentrations of FF right after pre-incubation (t = 0), indicating
a fast translocation of the drug and a fast onset of action. The
observation that the influence of the glucocorticoids was distinct
for certain cytokines might reflect differences in the regulation
and/or mechanisms of cytokine secretion [14]. Cytokines are
typically produced as response to T-cell receptor stimulations
either by upregulation of their transcription or by translation of
pre-existing mRNA transcripts [15].
The overall more pronounced anti-inflammatory activity of FF
compared to MF is highly consistent with the higher relative
receptor affinity (RRA) of FF compared to MF [6,16].
In our experimental setting the nasal mucosal cells were in
contact with the glucocorticoids typically for one hour, with the
readout performed 24–48 hours later; it can be assumed that
classical effects on transcription and translation of genes encoding
inflammatory mediators were responsible for the observations
[17]. Rapid effects or nongenomic actions also have been
described within seconds to a few minutes [18–23].
Although an inhibition of inflammatory mediators is the
prerequisite for clinical symptom management in allergic rhinitis,
the required magnitude and temporal relation of cytokine
suppression and the improvement of symptoms is not definite.
Lately, both the FDA and the EMA issued recommendations for
Figure 2. Nasal polyp tissue (n=9) was stimulated with SEB for 1 hour before incubation with FF and MP at 10211 to 1028 molar
concentrations for further 24 hours (post-challenge incubation). The figures show a concentration-dependent inhibition of cytokine release,
reaching significance at different concentrations per drug and cytokine. Significance is indicated vs. baseline (* p,0.05). Please refer to table 2 for a
comparison between drugs.
doi:10.1371/journal.pone.0093754.g002
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including the onset of action into the evaluation of drugs for
allergic rhinitis [24,25] which confer with the proposal of an
EAACI workshop group [26]. Efficacy of intranasal corticosteroids
can be expected after 7–8 hours of dosing, but some patients
appear to benefit more rapidly, e.g. within the first two hours
[2,27]. In case of rapid improvement of clinical symptoms
nongenomic glucocorticoid effects may play a role as well.
Limitations to this study include the fact that the clinical
importance of these observations is unknown, and that the
mechanisms underlying the observations are not identified. The
study also uses whole tissue fragments and is thus not suitable to
study effects on single cell components, but rather was aimed to
resemble the in vivo situation in humans as much as possible.
To summarize, in the present study we demonstrated the
potential of our human mucosal model and compared for the first
time the activity of two modern intranasal glucocorticoids
regarding inhibition of Th1, Th2 and Th17 cytokine release from
human nasal polyp tissue. Thereby, we employed pre- and post-
challenge incubations with FF or MF to mimic typical clinical
situations of preventive use or therapy after exposure to allergens.
All results revealed an uptake, receptor activation and prolonged
binding of the drugs in the mucosal tissue with a rapid uptake and
sustained suppression of cytokine release that was stronger for FF
compared to MF. While the maximal suppressive activity was not
different when FF was added before or after tissue stimulation with
SEB, the cytokine suppression capacity of MF appeared to be
compromised if the SEB induced cell activation preceded the drug
addition. In a pre-challenge incubation with removal of excess
drug concentrations MF approached inhibition of IL-5 and TNF-
a comparable to FF. However, this was only observed after 6 and
24 hours while FF maximally blocked the release of these
cytokines already right after pre-incubation and at concentrations
up to four degrees of magnitude lower than for MF. Furthermore,
there was a difference in the cytokines that were suppressed, with a
wider range of T helper signatures for FF compared to MF. These
data underline the high efficacy of FF in allergic and other
inflammatory diseases and indicate the necessity of head-to-head
comparison studies vs. MF and other corticosteroids in adequate
clinical settings using appropriate concentrations.
Figure 3. Nasal polyp tissue (n=9) was incubated with FF and MF at different concentrations for 1 hour, then washed and SEB was
added either immediately (0 hour), after 6 or 24 hours (pre-challenge incubation with time interval) Cells were then incubated for
another 24 hours.When SEB stimulation was performed immediately, FF demonstrated a faster onset of action with a significantly higher maximal
inhibition of all cytokines vs. MF. For most cytokines and time points, FF reaches a significant reduction at a lower concentration; however, when the
time interval between pre-incubation and challenge was minimally 6 hours, the suppression capacity of MF reached the same levels as FF for IL-5 and
TNF-a.
doi:10.1371/journal.pone.0093754.g003
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